Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Escherichia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: Escherichia. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2015-005706-11 Sponsor Protocol Number: Cyst2016_01 Start Date*: 2016-03-14
    Sponsor Name:Vita Green Europa S.A.
    Full Title: Single-site, open, randomized clinical trial to assess the non-inferiority of Cysticlean® versus Fosfomicina in the treatment of cystitis in women in Spain.
    Medical condition: Urinary Tract Infection (UTI)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10011790 Cystitis escherichia PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001448-78 Sponsor Protocol Number: Cyst2018_01 Start Date*: 2018-11-08
    Sponsor Name:Vita Green Europa S.A.
    Full Title: Single-site, open, randomized clinical trial to assess the non-inferiority of Cysticlean® versus Fosfomicina in the treatment of cystitis in women in Spain.
    Medical condition: Urinary Tract Infection (UTI)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10011790 Cystitis escherichia PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021413-23 Sponsor Protocol Number: 07-0036 Start Date*: 2010-09-28
    Sponsor Name:University of Athens, Medical School
    Full Title: Optimizing Dosing of Colistin for Infections Resistant to all Other Antibiotics
    Medical condition: Bloodstream infection (bacteremia) or hospital-acquired pneumonia by Gram-negative bacillus lacking susceptibility to all of the following antibiotics: cefepime OR ceftazidime, imipenem OR meropene...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060562 Bacteremia, unspecified LLT
    12.1 10064977 Acinetobacter bacteremia LLT
    12.1 10054228 Gram-negative bacteremia LLT
    12.1 10054279 Escherichia coli bacteremia LLT
    12.1 10054281 Escherichia bacteremia LLT
    12.1 10058883 Klebsiella bacteremia LLT
    12.1 10058884 Enterobacter bacteremia LLT
    12.1 10058925 Serratia bacteremia LLT
    12.1 10058926 Hemophilus bacteremia LLT
    12.1 10058927 Pseudomonal bacteremia LLT
    12.1 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005273-27 Sponsor Protocol Number: VAC52416BAC3001 Start Date*: 2021-09-07
    Sponsor Name:Janssen Vaccines & Prevention B.V
    Full Title: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal P...
    Medical condition: Invasive Extraintestinal Pathogenic Escherichia coli Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10052238 Escherichia urinary tract infection PT
    20.0 10021881 - Infections and infestations 10015295 Escherichia infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IT (Prematurely Ended) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002690-35 Sponsor Protocol Number: OEV123 Start Date*: 2017-05-08
    Sponsor Name:Scandinavian Biopharma AB
    Full Title: A randomized, placebo-controlled phase IIb (OEV 123) study to evaluate safety, immunogenicity, diagnostic methodology, and estimate vaccine efficacy of an oral enterotoxigenic Escherichia coli (ET...
    Medical condition: Healthy voluteers (prevention of diarrheal disease due to infection with enterotoxigenic E. coli [ETEC])
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10054242 Escherichia coli infection LLT
    19.1 100000004862 10044552 Traveller's diarrhea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-002110-32 Sponsor Protocol Number: 10-0065 Start Date*: 2018-06-13
    Sponsor Name:Regents of the University of Michigan
    Full Title: DMID Protocol Number: 10-0065 OVERCOME Trial: Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli
    Medical condition: Blood stream Infection (BSI) and/or pneumonia due to extensively drug-resistant Gram-negative bacilli (XDR-GNB) including XDR-AB, CRE and XDR-PA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10004031 Bacterial infection due to other gram-negative organisms LLT
    20.1 10021881 - Infections and infestations 10035701 Pneumonia gram-negative bacterial NOS LLT
    20.1 10021881 - Infections and infestations 10064977 Acinetobacter bacteremia LLT
    20.0 10021881 - Infections and infestations 10051190 Pneumonia Pseudomonas aeruginosa LLT
    20.0 10021881 - Infections and infestations 10035679 Pneumonia due to Escherichia coli (E. Coli) LLT
    20.0 10021881 - Infections and infestations 10054280 Escherichia coli bacteraemia LLT
    20.0 10021881 - Infections and infestations 10021860 Infection Pseudomonas aeruginosa LLT
    20.1 10021881 - Infections and infestations 10023456 Klebsiella pneumonia LLT
    20.0 10021881 - Infections and infestations 10058883 Klebsiella bacteremia LLT
    20.0 10021881 - Infections and infestations 10054218 Enterobacter pneumonia PT
    20.1 10021881 - Infections and infestations 10058884 Enterobacter bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002922-21 Sponsor Protocol Number: FOREST Start Date*: 2014-05-07
    Sponsor Name:FISEVI
    Full Title: Randomized, phase III, multicentre, open-labelled clinical trial, to evaluate the efficacy of fosfomycin vs meropenem in the treatment of bacteremic urinary tract infection caused by Escherichia co...
    Medical condition: Bacteremic urinary tract infection by Escherichia coli extended spectrum beta-lactamase (ESBL).
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10052238 Escherichia urinary tract infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002222-46 Sponsor Protocol Number: 36688 Start Date*: 2013-09-04
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: In vivo effects of C1-esterase inhibitor on innate immune response during endotoxemia in human - VECTOR-II study A randomized controlled pilot study
    Medical condition: Inflammation, SIRS and endotoxemia
    Disease: Version SOC Term Classification Code Term Level
    15.1 10018065 - General disorders and administration site conditions 10061218 Inflammation PT
    15.1 10021881 - Infections and infestations 10060412 Septicaemia due to Escherichia coli (E. coli) LLT
    15.1 100000004848 10051553 Complement factor C1 LLT
    15.1 10021881 - Infections and infestations 10040047 Sepsis PT
    15.1 10018065 - General disorders and administration site conditions 10062357 SIRS LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001240-19 Sponsor Protocol Number: CSL16001 Start Date*: 2016-08-22
    Sponsor Name:Synlogic
    Full Title: Clearance of the probiotic strain Escherichia coli Nissle 1917 in the gastrointestinal tract of healthy volunteers
    Medical condition: Healthy volunteers trial, intended indication: Colitis ulcerosa in phase of remission, Chronic constipation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-001541-13 Sponsor Protocol Number: OEV-125 Start Date*: 2021-07-27
    Sponsor Name:Scandinavian Biopharma Holding AB
    Full Title: A Phase 2 immunological bridging study assessing the non-inferiority of a new formulation of ETVAX®. A prospective double-blind, randomized study in healthy volunteers
    Medical condition: Healthy volunteers (prevention of diarrheal disease due to infection with enterotoxigenic E. coli [ETEC])
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004865 10054983 Prophylaxis against traveller's diarrhea LLT
    20.1 100000004862 10022665 Intestinal infection due to enterotoxigenic E. coli LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003792-19 Sponsor Protocol Number: FOS-PROST-001 Start Date*: 2021-03-04
    Sponsor Name:Hospital Universitari Mutua Terrassa
    Full Title: Fosfomycin as an oral alternative treatment for acute bacterial prostatitis due to multi-drug resistant Escherichia coli. Pilot study
    Medical condition: Acute bacterial prostatitis due to multi-drug resistant Escherichia coli
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004531-36 Sponsor Protocol Number: MU1646 Start Date*: 2018-09-03
    Sponsor Name:Ardeypharm GmbH
    Full Title: Escherichia coli strain Nissle 1917 - Suspension for treatment of patients with Clostridium difficile associated diarrhoea
    Medical condition: Clostridium difficile associated diarrhoea (CDAD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002691-17 Sponsor Protocol Number: C11-001 Start Date*: 2011-07-06
    Sponsor Name:ALEXION PHARMA INTERNATIONAL SARL
    Full Title: An open label, multi-center trial of eculizumab in patients with Shiga-toxin producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)
    Medical condition: Shiga-Toxin producing Escherichia Coli Hemolytic-Uremic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10019515 Hemolytic uremic syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002343-99 Sponsor Protocol Number: 1.0 Start Date*: 2012-01-03
    Sponsor Name:Heart of England NHS Foundation Trust
    Full Title: An Open-label Study into the Efficacy and Dosing of Probiotic Escherichia coli Nissle 1917 for Prevention of Gram-negative Gastric Colonisation in Ventilated Intensive Care Patients.
    Medical condition: Gastric colonisation by pathogenic gram negative bacteria in ventilated adult ICU patients and it's prevention by the probiotic E.coli Nissle 1917
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011446-26 Sponsor Protocol Number: 2009-011446-26 Start Date*: 2011-07-04
    Sponsor Name:Uppsala University
    Full Title: A randomized, placebo-controlled, double blind, parallel group phase II study of anti-ESBL IgY for the eradication of ESBL Klebsiella pneumoniae and Escherichia coli in faeces in carriers
    Medical condition: Feacal carriage of ESBL producing Klebsiella pneumoniae and/or E. coli.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004626-28 Sponsor Protocol Number: SymSF2 Start Date*: 2019-07-18
    Sponsor Name:SymbioPharm GmbH
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in pati...
    Medical condition: Diarrhoea-predominant irritable bowel syndrome with recurrent abdominal pain according to Rome IV criteria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003793-26 Sponsor Protocol Number: 3066K1-3311-WW Start Date*: 2008-05-19
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma
    Medical condition: First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FR (Completed) BE (Completed) PT (Completed) CZ (Completed) DE (Completed) SK (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000868-34 Sponsor Protocol Number: ZKES-EcNO-2015 Start Date*: 2015-05-29
    Sponsor Name:ZKES GmbH
    Full Title: Randomized, placebo controlled phase III trial of a microbiological concomitant therapy/prevention of chemotherapeutical induced diarrhea (caused by inflammation and an impaired intestinal barrier)...
    Medical condition: Gastric or colorectal cancers, where a treatment with 5-Fluoruracil and one further chemotherapeutic remedy (either irinotecan or a platinum based chemotherapeutic remedy) is planned.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004961-14 Sponsor Protocol Number: UV2013/4 Start Date*: 2014-06-11
    Sponsor Name:Kliniken Kärnan Urology Centre
    Full Title: Pilot study to investigate the mode of action (MoA) of Uro-Vaxom® on a molecular level in pre-menopausal women suffering from recurrent urinary tract infections (rUTI)
    Medical condition: Recurrent urinary tract infections (rUTI)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10038140 Recurrent urinary tract infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006335-12 Sponsor Protocol Number: Ecorhino Start Date*: 2008-11-18
    Sponsor Name:Prof. Dr. med. Margitta Worm
    Full Title: Explorative analysis of the immunmodulatory capacities of apathogenic Escherichia coli Nissle 1917 in patients with rhinoconjunctivitis due to grass pollen allergy.
    Medical condition: Due to the worldwide increasing prevalence of allergic rhinoconjunctivitis (AR), new therapeutical strategies are needed. The symptomatic treatment with topical and systemic antihistamines and cort...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 11:31:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA